Please login to the form below
RA
This page shows the latest RA news and features for those working in and with pharma, biotech and healthcare.
Gilead and EVOQ Therapeutics partner in deal potentially worth over $650m
Gilead and EVOQ Therapeutics (EVOQ) have entered into a collaboration and licensing agreement aimed at advancing immunotherapies for the treatment of rheumatoid arthritis (RA) and lupus. ... We look forward to working with the Gilead team to advance new
Latest news
-
Roche’s COVID-19 antibody receives FDA approval for hospitalised adults
Like Actemra, which was approved in 2010 to treat rheumatoid arthritis, Kineret has been on the US market for more than two decades for the treatment of RA, and has been
-
AbbVie receives extended SMC recommendation for Rinvoq in rheumatoid arthritis patients
The treatment was previously reimbursed by the SMC for those with severe RA. ... Typically, most patients develop RA between the age of 40 and 60, but the condition can affect people of any age.
-
Astellas to support development of Taysha’s AAV-based gene therapy programmes
Also commenting on the deal, RA Session II, Taysha’s chief executive officer, said: “We are excited to enter this strategic investment with Astellas, a premier biopharmaceutical company with global
-
NICE recommends Grifols’ Tavlesse for chronic immune thrombocytopenia
With NICE’s recommendation, which is specifically for patients who have previously had a TPO-RA, or who are unable to receive a TPO-RA, Tavlesse can now be accessed and
-
NHS Scotland to offer Jyseleca for patients with moderate rheumatoid arthritis
More than 40, 000 people in Scotland live with RA and an estimated 35% of those will have moderate disease activity. ... With RA, the sooner a patient’s treatment starts, the better chance there is of delaying disease progression.
More from news
Approximately 9 fully matching, plus 162 partially matching documents found.
Latest Intelligence
-
Alzheimer’s: the search for a cure
Similar retrospective positive findings were recently published for the anti-diabetic, glucagon-like peptide-1 receptor agonist (GLP1-RA), which was also found to reduce neuroinflammation.
-
Setting up for success in a post-Brexit, post-pandemic Britain
and Rheumatoid Arthritis (RA). ... More than 400, 000 people in the UK live with RA (around 380, 000 in England), and it is recognised as a condition that can cause debilitating physical pain, affect mental
-
Drug launches to watch in 2019
The good news for the company is that it has not one but two potential blockbusters likely to gain approval in 2019: Upadacitinib (AbbVie) for RA and risankizumab (co-marketed with ... Likewise, upadacitinib will face competition in both RA and atopic
-
Deal Watch January 2018
Royalty monetisation. 230. Jiangsu Hengrui Medicine/Arcutis. SHR0302, selective JAK inhibitor, for dermatology disorders (currently p2 for RA in China).
-
European CTR implementation advances ethical assessment of clinical trials
Timelines are becoming stricter with regard to the fact that compatibility with Regulatory Authority (RA) assessment must be ensured. ... Per the 2001/20/EC directive, assessment was independent from RA and this rule has created more flexibility for EC
More from intelligence
Approximately 0 fully matching, plus 24 partially matching documents found.
Latest from PMHub
-
Food Allergy – Is avoidance the only option?
Accessed May 11, 2022. Jones SM, Kim EH, Nadeau KC, Nowak-Wegrzyn A, Wood RA, Sampson HA.
-
Understanding behaviour change: A Porterhouse Insights specialism
Annu Rev Psychol 2015; 66: 799–823. 5. Ferrer RA and Mendes WB.
-
RA Consultants Private Limited
RA Consultants Private Limited.
-
The other side of … rheumatoid arthritis
So when blood tests came back normal, she felt confident to pursue referral until RA was confirmed.
-
Lucid Group reaches the finals of the PM360 2020 Trailblazer Initiative Awards
LiBRA is a multichannel program, focused on inspiring and enabling clinical behavior change to achieve better disease control for patients with RA. ... Lisa Druce, Managing Director, Lighthouse Medical Communications US, commented “RA is a chronic
More from PMHub
Approximately 1 fully matching, plus 28 partially matching documents found.
Subscribe to our email news alerts
- Contagious Conversations: Exploring Infectious Disease in the Digital Age
- Austrian State Secretary to speak at FlyPharma Europe 2023
- Further data for AstraZeneca/Daichii Sankyo’s Enhertu for breast cancer requested by NICE
- Gritstone Bio receives $433m BARDA contract for COVID-19 vaccine candidate
- EDX Medical Group develops multi-disease 'point-of-care' rapid tests for cancer, infections and cardiovascular conditions
- ScreenPoint Medical to showcase AI software at European scientific meeting
No results were found
PMHub
Blue Latitude Health
Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
